Immunotherapy Biomarkers and Patient Selection
Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.
http://cancergrace.org/cancer-treatments/2016/01/20/io_2015_brahmer_biomarkers_patient_selection/
Видео Immunotherapy Biomarkers and Patient Selection канала GRACE - Global Resource for Advancing Cancer Education
http://cancergrace.org/cancer-treatments/2016/01/20/io_2015_brahmer_biomarkers_patient_selection/
Видео Immunotherapy Biomarkers and Patient Selection канала GRACE - Global Resource for Advancing Cancer Education
Показать
Комментарии отсутствуют
Информация о видео
20 января 2016 г. 23:29:23
00:24:18
Другие видео канала
Tumour immunology and immunotherapy
Tumor Microenvironment and PD-L1 biomarker
ASCO 2021 Lung Recap: Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo Alone
Cancer Immunotherapy - PD-1 and PD-L1
The future in multiple myeloma: BiTE immunotherapy, CAR-T, and immune checkpoint inhibitors
Biomarkers in Cancer Immunotherapy: How Much Do They Matter?
The Role of Biomarkers in Clinical Trials
Locating Brain Tumors with Brain Mapping & Surgical Planning
ASCO 2021 Lung Recap: Circulatory Tumor DNA
ASCO 2021 Lung: Amivantamab + Lazertinib in EGFR, Patritumab Deruxtecan in EGFR+ Acquired Resistance
IDDI WEBINAR: Biomarker based clinical trial designs
For Cancer Patients, Biomarkers Matter
How does cancer immunotherapy work?
Long-Term Side Effects of Brain Tumor Treatment
What is the Biomarker Discovery Program?
Mismatch repair
Biomarker Discovery, Quantitation, and Analysis with Multiplex Immunoassays
Biomarkers in Cancer Immunotherapy: What Patients Need to Know
PET scan results- Lymphoma
Biomarkers